Markus R Meyer

List of Publications by Year
in descending order

179	5,604	76294	114418
papers	citations	40 h-index	63 g-index

187	187	187	3940
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatographyâ€“mass spectrometry. Analytical and Bioanalytical Chemistry, 2010, 397, 1225-1233.	1.9	246
2	Measuring biomarkers in wastewater as a new source of epidemiological information: Current state and future perspectives. Environment International, 2017, 99, 131-150.	4.8	209
3	Studies on the metabolism of the Î±â€pyrrolidinophenone designer drug methylenedioxyâ€pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GCâ€“MS and LCâ€“highâ€resolution MS and its detectability in urine by GCâ€“MS. Journal of Mass Spectrometry, 2010, 45, 1426-1442.	0.7	168
4	Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept. Analytical and Bioanalytical Chemistry, 2011, 400, 3481-3489.	1.9	132
5	Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultra-high-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionizat. Rapid Communications in Mass Spectrometry, 2010, 24, 3103-3108.	0.7	127
6	Automated Mass Spectral Deconvolution and Identification System for GC-MS Screening for Drugs, Poisons, and Metabolites in Urine. Clinical Chemistry, 2010, 56, 575-584.	1.5	120
7	Orbitrap technology for comprehensive metabolite-based liquid chromatographicâ€“high resolution-tandem mass spectrometric urine drug screening â€“ Exemplified for cardiovascular drugs. Analytica Chimica Acta, 2015, 891, 221-233.	2.6	116
8	Development of the first metabolite-based LC-MS n urine drug screening procedure-exemplified for antidepressants. Analytical and Bioanalytical Chemistry, 2011, 400, 79-88.	1.9	112
9	Systematic investigation of ion suppression and enhancement effects of fourteen stableâ€isotopeâ€labeled internal standards by their native analogues using atmosphericâ€pressure chemical ionization and electrospray ionization and the relevance for multiâ€analyte liquid chromatographic/mass spectrometric procedures. Rapid Communications in Mass Spectrometry, 2010, 24, 859-867.	0.7	103
10	Metabolism of Designer Drugs of Abuse: An Updated Review. Current Drug Metabolism, 2010, 11, 468-482.	0.7	100
11	The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers. Drug Metabolism and Disposition, 2008, 36, 2345-2354.	1.7	88
12	Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics, 2011, 12, 215-233.	0.6	88
13	High-resolution mass spectrometry in toxicology: current status and future perspectives. Archives of Toxicology, 2016, 90, 2161-2172.	1.9	86
14	New cathinoneâ€derived designer drugs 3â€bromomethcathinone and 3â€fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GCâ€“MS and LCâ€“highâ€resolution MS and their detectability in urine. Journal of Mass Spectrometry, 2012, 47, 253-262.	0.7	84
15	New designer drug Î±â€pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. Journal of Mass Spectrometry, 2009, 44, 952-964.	0.7	83
16	Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices â€“ Where do we stand today?. Analytica Chimica Acta, 2016, 927, 13-20.	2.6	83
17	Current applications of high-resolution mass spectrometry in drug metabolism studies. Analytical and Bioanalytical Chemistry, 2012, 403, 1221-1231.	1.9	79
18	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clinical Research in Cardiology, 2015, 104, 1097-1105.	1.5	76

#	Article	IF	Citations
19	Fast and simple procedure for liquidâ€“liquid extraction of 136 analytes from different drug classes for development of a liquid chromatographic-tandem mass spectrometric quantification method in human blood plasma. Analytical and Bioanalytical Chemistry, 2010, 397, 2303-2314.	1.9	67
20	2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Analytical and Bioanalytical Chemistry, 2013, 405, 3125-3135.	1.9	67
21	Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS. Analytical and Bioanalytical Chemistry, 2015, 407, 6697-6719.	1.9	66
22	New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics. Archives of Toxicology, 2016, 90, 2421-2444.	1.9	63
23	In vitro approaches to studying the metabolism of new psychoactive compounds. Drug Testing and Analysis, 2011, 3, 483-495.	1.6	62
24	Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques. Analytical and Bioanalytical Chemistry, 2015, 407, 1371-1388.	1.9	61
25	Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography-high-resolution mass spectrometry for drug testing purposes. Analytical and Bioanalytical Chemistry, 2016, 408, 3571-3591.	1.9	60
26	Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma. Analytica Chimica Acta, 2017, 965, 83-95.	2.6	60
27	Chiral drug analysis using mass spectrometric detection relevant to research and practice in clinical and forensic toxicology. Journal of Chromatography A, 2012, 1269, 122-135.	1.8	58
28	Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDBD, butylone, MDPPP, MDPV, MDPB, 5-MAPB, and 5-API as examples. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 32-42.	1.4	55
29	A validated GC-MS procedure for fast, simple, and cost-effective quantification of glycols and GHB in human plasma and their identification in urine and plasma developed for emergency toxicology. Analytical and Bioanalytical Chemistry, 2011, 400, 411-414.	1.9	52
30	Paper Spray Ionization Coupled to High Resolution Tandem Mass Spectrometry for Comprehensive Urine Drug Testing in Comparison to Liquid Chromatography-Coupled Techniques after Urine Precipitation or Dried Urine Spot Workup. Analytical Chemistry, 2017, 89, 11779-11786.	3.2	51
31	Studies on the metabolism and toxicological detection of the new designer drug 4â€²-methyl-Î±-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 824, 81-91.	1.2	49
32	New psychoactive substances: Studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-Î±-PVP, 25-I-NBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine. Toxicology Letters, 2017, 280, 142-150.	0.4	49
33	Studies on the metabolism of the Î”9â€¢tetrahydrocannabinol precursor Î”9â€¢tetrahydrocannabinolic acid A (Î”9â€¢THCAâ€¢A) in rat using LCâ€¢MS/MS, LCâ€¢QTOF MS and GCâ€¢MS techniques. Journal of Mass Spectrometry, 2009, 44, 1423-1433.	2.2	48
34	Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Analytical and Bioanalytical Chemistry, 2011, 400, 127-135.	1.9	47
35	Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clinical Toxicology, 2011, 49, 691-693.	0.8	45
36	Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MS n. Analytical and Bioanalytical Chemistry, 2013, 405, 6307-6321.	1.9	45

#	Article	IF	Citations
37	Direct analysis of the mushroom poisons Î±- and Î²-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to liquid chromatographyâ€“high resolution-mass spectrometry/mass spectrometry. Journal of Chromatography A, 2014, 1325, 92-98.	1.8	43
38	Elucidation of the metabolites of the novel psychoactive substance 4â€²methylâ€²Nâ€²ethylâ€²cathinone (4â€²MEC) in human urine and pooled liver microsomes by GCâ€“MS and LCâ€“HRâ€“MS/MS techniques and of its detectability by GCâ€“MS or LCâ€“MSⁿ standard screening approaches. Drug Testing and Analysis, 2015, 7, 368-375.	1.6	43
39	Current position of high-resolution MS for drug quantification in clinical & forensic toxicology. Bioanalysis, 2014, 6, 2275-2284.	0.6	41
40	Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GCâ€“MS, LCâ€“MS n , and LCâ€“HRâ€“MSâ€“MS. Analytical and Bioanalytical Chemistry, 2015, 407, 7831-7842.	1.9	41
41	What is the contribution of human FMO3 in the N -oxygenation of selected therapeutic drugs and drugs of abuse?. Toxicology Letters, 2016, 258, 55-70.	0.4	41
42	Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatographyâ€“linear ion trapâ€“mass spectrometry (LC-MSn). Analytical and Bioanalytical Chemistry, 2012, 402, 1249-1255.	1.9	40
43	Tools for studying the metabolism of new psychoactive substances for toxicological screening purposes â€“ A comparative study using pooled human liver S9, HepaRG cells, and zebrafish larvae. Toxicology Letters, 2019, 305, 73-80.	0.4	40
44	Full validation and application of an ultra high performance liquid chromatographic-tandem mass spectrometric procedure for target screening and quantification of 34 antidepressants in human blood plasma as part of a comprehensive multi-analyte approach. Analytical and Bioanalytical Chemistry, 2011, 400, 2093-2107.	1.9	39
45	Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N- [(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)- N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GCâ€“MS, LCâ€“MS n , and LCâ€“HRâ€“MS/MS approaches. Journal of Pharmaceutical and Biomedical Analysis, 2017, 134, 158-169.	1.4	39
46	Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicology Letters, 2014, 230, 28-35.	0.4	37
47	First report on the pharmacokinetics of tramadol and O-desmethyltramadol in exhaled breath compared to plasma and oral fluid after a single oral dose. Biochemical Pharmacology, 2015, 98, 502-510.	2.0	37
48	Enantioselectivity in the Methylation of the Catecholic Phase I Metabolites of Methylenedioxy Designer Drugs and Their Capability To Inhibit Catechol-O-methyltransferase-Catalyzed Dopamine 3-Methylation. Chemical Research in Toxicology, 2009, 22, 1205-1211.	1.7	36
49	Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents. Analytical and Bioanalytical Chemistry, 2012, 402, 195-208.	1.9	36
50	A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 Î²-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Analytical and Bioanalytical Chemistry, 2014, 406, 225-237.	1.9	34
51	Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Analytical and Bioanalytical Chemistry, 2016, 408, 6283-6294.	1.9	34
52	Untargeted metabolomics by high resolution mass spectrometry coupled to normal and reversed phase liquid chromatography as a tool to study the in vitro biotransformation of new psychoactive substances. Scientific Reports, 2019, 9, 2741.	1.6	34
53	In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Analytical and Bioanalytical Chemistry, 2019, 411, 4751-4763.	1.9	34
54	Analytical Toxicology of Emerging Drugs of Abuseâ€”An Update. Therapeutic Drug Monitoring, 2012, 34, 615-621.	1.0	32

#	Article	IF	Citations
55	Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat urine using GCâ€MS, LCâ€MSⁿ and LCâ€highâ€resolution MSⁿ. Journal of Mass Spectrometry, 2013, 48, 24-41.	0.7	32
56	Towards a universal LCâ€“MS screening procedure â€“ can an LIT LCâ€“MSⁿ screening approach and reference library be used on a quadrupoleâ€LIT hybrid instrument?. Journal of Mass Spectrometry, 2012, 47, 66-71.	0.7	31
57	Studies on the microbial biotransformation of the novel psychoactive substance methylenedioxypyrovalerone (MDPV) in wastewater by means of liquid chromatography-high resolution mass spectrometry/mass spectrometry. Science of the Total Environment, 2014, 493, 588-595.	3.9	31
58	How to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screeningsâ€”A Follow-Up Study Comparing Pooled Human Liver S9, HepaRG Cells, and Zebrafish Larvae. Frontiers in Chemistry, 2020, 8, 539.	1.8	31
59	Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MS n. Analytical and Bioanalytical Chemistry, 2014, 406, 1957-1974.	1.9	30
60	The Role of Human UDP-Glucuronyltransferases on the Formation of the Methylenedioxymethamphetamine (Ecstasy) Phase II MetabolitesR- andS-3-Methoxymethamphetamine 4-O-Glucuronides. Drug Metabolism and Disposition, 2009, 37, 2212-2220.	1.7	28
61	Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicology Letters, 2015, 232, 159-166.	0.4	28
62	In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Archives of Toxicology, 2016, 90, 305-318.	1.9	28
63	Dried urine spots - A novel sampling technique for comprehensive LC-MSn drug screening. Analytica Chimica Acta, 2017, 982, 112-121.	2.6	28
64	Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatographyâ€“high resolution mass spectrometry. Drug Testing and Analysis, 2018, 10, 496-506.	1.6	28
65	Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry. Talanta, 2018, 176, 635-645.	2.9	28
66	P-glycoprotein interactions of novel psychoactive substances â€“ Stimulation of ATP consumption and transport across Caco-2 monolayers. Biochemical Pharmacology, 2015, 94, 220-226.	2.0	27
67	Automated optimization of XCMS parameters for improved peak picking of liquid chromatographyâ€“mass spectrometry data using the coefficient of variation and parameter sweeping for untargeted metabolomics. Drug Testing and Analysis, 2019, 11, 752-761.	1.6	26
68	Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochemical Pharmacology, 2009, 77, 1725-1734.	2.0	25
69	Metabolism of the tryptamineâ€derived new psychoactive substances 5â€MeOâ€2â€Meâ€DALT, 5â€MeOâ€2â€Meâ€ALCHT, and 5â€MeOâ€2â€Meâ€DIPT and their detectability in urine studied by GCâ€“MS, LCâ€“MSⁿ, and LCâ€HRâ€MS/MS. Drug Testing and Analysis, 2018, 10, 184-195.	2.5	25
70	LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques. Analytical and Bioanalytical Chemistry, 2018, 410, 897-912.	1.9	24
71	Altered glucocorticoid metabolism represents a feature of macrophâ€aging. Aging Cell, 2020, 19, e13156.	3.0	24
72	The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers. Drug Metabolism and Disposition, 2009, 37, 1152-1156.	1.7	23

#	Article	IF	Citations
73	Urinary Excretion Kinetics of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) and Its Phase I and Phase II Metabolites in Humans following Controlled MDMA Administration. Clinical Chemistry, 2011, 57, 1748-1756.	1.5	23
74	The in vivo and in vitro metabolism and the detectability in urine of 3â€™,4â€™â€methylenedioxyâ€alphaâ€pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenoneâ€type designer drug, studied by GCâ€MS and LCâ€MSⁿ. Drug Testing and Analysis, 2014, 6, 746-756.	1.6	23
75	Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MSn techniques. Analytical and Bioanalytical Chemistry, 2015, 407, 3457-3470.	1.9	23
76	Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212â€2 studied using in vitro tools and LCâ€HRâ€MS/MS. Drug Testing and Analysis, 2016, 8, 1039-1048.	1.6	23
77	Different in vitro and in vivo tools for elucidating the human metabolism of alphaâ€cathinoneâ€derived drugs of abuse. Drug Testing and Analysis, 2018, 10, 1119-1130.	1.6	23
78	Metabolic fate of the new synthetic cannabinoid 7â€™Nâ€5Fâ€ADB in rat, human, and pooled human S9 studied by means of hyphenated highâ€resolution mass spectrometry. Drug Testing and Analysis, 2019, 11, 305-317.	1.6	23
79	Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. Toxicology Letters, 2011, 202, 120-128.	0.4	22
80	Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. Biochemical Pharmacology, 2012, 83, 131-138.	2.0	22
81	In situ antibiofilm effect of glass-ionomer cement containing dimethylaminododecyl methacrylate. Dental Materials, 2015, 31, 992-1002.	1.6	22
82	Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD). Neuropharmacology, 2020, 172, 107856.	2.0	22
83	Lefetamineâ€derived designer drugs Nâ€ethylâ€1,2â€diphenylethylamine (NEDPA) and Nâ€isoâ€propylâ€1,2â€diphenylethylamine (NPDPA): Metabolism and detectability in rat urine using GCâ€MS, LCâ€MSⁿ and LCâ€HRâ€MS/MS. Drug Testing and Analysis, 2014, 6, 1038-1048.	1.6	21
84	Comparison of Three Untargeted Data Processing Workflows for Evaluating LC-HRMS Metabolomics Data. Metabolites, 2020, 10, 378.	1.3	21
85	Studies on the metabolism and detectability of the designer drug Î²â€naphyrone in rat urine using GCâ€MS and LCâ€HRâ€MS/MS. Drug Testing and Analysis, 2013, 5, 259-265.	1.6	20
86	Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatographyâ€“linear ion-trap (high-resolution) mass spectrometry. Analytical and Bioanalytical Chemistry, 2014, 406, 1845-1854.	1.9	20
87	Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicology Letters, 2016, 241, 82-94.	0.4	20
88	LC-HR-MS/MS standard urine screening approach: Pros and cons of automated on-line extraction by turbulent flow chromatography versus dilute-and-shoot and comparison with established urine precipitation. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1043, 138-149.	1.2	20
89	In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. Toxicology Letters, 2017, 272, 84-93.	0.4	20
90	Toxicokinetics and Analytical Toxicology of Flualprazolam: Metabolic Fate, Isozyme Mapping, Human Plasma Concentration and Main Urinary Excretion Products. Journal of Analytical Toxicology, 2020, 44, 549-558.	1.7	20

#	Article	IF	Citations
91	Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4â€²-Methyl-Î±-pyrrolidinobutyrophenone. Drug Metabolism and Disposition, 2008, 36, 163-168.	1.7	19
92	Development, Validation, and Application of a Fast and Simple GCâ€“MS Method for Determination of Some Therapeutic Drugs Relevant in Emergency Toxicology. Therapeutic Drug Monitoring, 2011, 33, 649-653.	1.0	19
93	Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicology Letters, 2018, 285, 1-8.	0.4	19
94	Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence. Analytica Chimica Acta, 2019, 1070, 69-79.	2.6	19
95	Drug Administration Routes Impact the Metabolism of a Synthetic Cannabinoid in the Zebrafish Larvae Model. Molecules, 2020, 25, 4474.	1.7	19
96	Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4Â´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine. Archives of Toxicology, 2020, 94, 2009-2025.	1.9	19
97	Case report of accidental poisoning with the tranquilizer xylazine and the anesthetic ketamine confirmed by qualitative and quantitative toxicological analysis using GCâ€MS and LCâ€MSⁿ. Drug Testing and Analysis, 2013, 5, 785-789.	1.6	18
98	Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS. Analytical and Bioanalytical Chemistry, 2017, 409, 1681-1695.	1.9	18
99	In vitro glucuronidation of designer benzodiazepines by human UDPâ€glucuronyltransferases. Drug Testing and Analysis, 2019, 11, 45-50.	1.6	18
100	Toxicokinetic studies of the four new psychoactive substances 4-chloroethcathinone, N-ethylnorpentylone, N-ethylhexedrone, and 4-fluoro-alpha-pyrrolidinohexiophenone. Forensic Toxicology, 2020, 38, 59-69.	1.4	18
101	Toxicometabolomics of the new psychoactive substances Î±-PBP and Î±-PEP studied in HepaRG cell incubates by means of untargeted metabolomics revealed unexpected amino acid adducts. Archives of Toxicology, 2020, 94, 2047-2059.	1.9	18
102	Screening for illicit drugs in pooled human urine and urinated soil samples and studies on the stability of urinary excretion products of cocaine, MDMA, and MDEA in wastewater by hyphenated mass spectrometry techniques. Drug Testing and Analysis, 2017, 9, 106-114.	1.6	17
103	Power of Orbitrapâ€based LCâ€high resolutionâ€MS/MS for comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after onâ€spot cleavage in comparison to established LCâ€“MSⁿ or GCâ€“MS procedures. Drug Testing and Analysis, 2018, 10, 158-163.	1.6	17
104	Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine. Talanta, 2018, 188, 111-123.	2.9	17
105	Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. Toxicology Letters, 2009, 190, 54-60.	0.4	16
106	Investigation on the Enantioselectivity of the Sulfation of the Methylenedioxymethamphetamine Metabolites 3,4-Dihydroxymethamphetamine and 4-Hydroxy-3-Methoxymethamphetamine using the Substrate-Depletion Approach. Drug Metabolism and Disposition, 2011, 39, 1998-2002.	1.7	16
107	Methylenedioxy designer drugs: Mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. Analytica Chimica Acta, 2014, 822, 37-50.	2.6	16
108	Analytical characterization of bioactive N -benzyl-substituted phenethylamines and 5-methoxytryptamines. Rapid Communications in Mass Spectrometry, 2015, 29, 573-584.	0.7	16

#	Article	IF	Citations
109	A new approach towards biomarker selection in estimation of human exposure to chiral chemicals: a case study of mephedrone. Scientific Reports, 2017, 7, 13009.	1.6	16
110	Distribution of the (synthetic) cannabinoids JWH-210, RCS-4, as well as â^†9-tetrahydrocannabinol following pulmonary administration to pigs. Archives of Toxicology, 2019, 93, 2211-2218.	1.9	16
111	Development, validation, and application of a quantitative volumetric absorptive microsamplingâ€“based method in finger prick blood by means of LC-HRMS/MS applicable for adherence monitoring of antipsychotics. Analytical and Bioanalytical Chemistry, 2021, 413, 1729-1737.	1.9	16
112	3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: Studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques. Journal of Pharmaceutical and Biomedical Analysis, 2016, 128, 485-495.	1.4	15
113	Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MS. Talanta, 2020, 213, 120847.	2.9	15
114	Studies on the in vivo contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. Biochemical Pharmacology, 2013, 86, 1497-1506.	2.0	14
115	Studies on the in vitro and in vivo metabolism of the synthetic opioids U-51754, U-47931E, and methoxyacetylfentanyl using hyphenated high-resolution mass spectrometry. Scientific Reports, 2019, 9, 13774.	1.6	14
116	Cytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay. Toxicology Letters, 2019, 301, 79-89.	0.4	14
117	Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring. Clinical Chemistry and Laboratory Medicine, 2020, 58, 664-672.	1.4	14
118	Analysis of Î±- and Î²-amanitin in Human Plasma at Subnanogram per Milliliter Levels by Reversed Phase Ultra-High Performance Liquid Chromatography Coupled to Orbitrap Mass Spectrometry. Toxins, 2020, 12, 671.	1.5	14
119	Michaelisâ€“Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicology Letters, 2013, 217, 137-142.	0.4	13
120	Toxicokinetics of novel psychoactive substances: Characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. Toxicology Letters, 2014, 227, 124-128.	0.4	13
121	Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MS n , and LC-high-resolution-MS n. Analytical and Bioanalytical Chemistry, 2015, 407, 831-843.	1.9	13
122	Multiple stage MS in analysis of plasma, serum, urine and in vitro samples relevant to clinical and forensic toxicology. Bioanalysis, 2016, 8, 457-481.	0.6	13
123	Interactions of phenethylamineâ€derived psychoactive substances of the 2Câ€series with human monoamine oxidases. Drug Testing and Analysis, 2019, 11, 318-324.	1.6	13
124	Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP). Journal of Mass Spectrometry, 2015, 50, 1163-1174.	0.7	12
125	Toxicokinetics of lefetamine and derived diphenylethylamine designer drugsâ€”Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicology Letters, 2015, 238, 39-44.	0.4	12
126	Phenethylamineâ€derived new psychoactive substances 2Câ€Eâ€FLY, 2Câ€EFâ€FLY, and 2Câ€Tâ€7â€FLY: Investigations on their metabolic fate including isoenzyme activities and their toxicological detectability in urine screenings. Drug Testing and Analysis, 2019, 11, 1507-1521.	1.6	12

#	Article	IF	Citations
127	In vitro toxicokinetics and analytical toxicology of three novel NBOMe derivatives: phase I and II metabolism, plasma protein binding, and detectability in standard urine screening approaches studied by means of hyphenated mass spectrometry. Forensic Toxicology, 2020, 38, 141-159.	1.4	12
128	Dimethocaine, a synthetic cocaine derivative: Studies on its in vitro metabolism catalyzed by P450s and NAT2. Toxicology Letters, 2014, 225, 139-146.	0.4	11
129	Toxicokinetics of NPS: Update 2017. Handbook of Experimental Pharmacology, 2018, 252, 441-459.	0.9	11
130	Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drugâ€“drug interactions of drugs of abuse. Archives of Toxicology, 2018, 92, 2875-2884.	1.9	11
131	Blood plasma level determination using an automated LCâ€“MSⁿ screening system and electronically stored calibrations exemplified for 22 drugs and two active metabolites often requested in emergency toxicology. Drug Testing and Analysis, 2019, 11, 102-111.	1.6	11
132	Toxicokinetics and analytical toxicology of the abused opioid Uâ€48800 â€" in vitro metabolism, metabolic stability, isozyme mapping, and plasma protein binding. Drug Testing and Analysis, 2019, 11, 1572-1580.	1.6	11
133	The metabolic fate of two new psychoactive substances â^' 2â€aminoindane and Nâ€methylâ€2â€aminoindane â^' studied in vitro and in vivo to support drug testing. Drug Testing and Analysis, 2020, 12, 145-151.	1.6	11
134	Flubromazolam-Derived Designer Benzodiazepines: Toxicokinetics and Analytical Toxicology of Clobromazolam and Bromazolam. Journal of Analytical Toxicology, 2021, 45, 1014-1027.	1.7	11
135	Are pigs a suitable animal model for in vivo metabolism studies of new psychoactive substances? A comparison study using different in vitro/in vivo tools and U-47700 as model drug. Toxicology Letters, 2020, 329, 12-19.	0.4	11
136	Studies on the metabolism and detectability of the emerging drug of abuse diphenylâ€2â€pyrrolidinemethanol (D2PM) in rat urine using GCâ€MS and LCâ€HRâ€MS/MS. Journal of Mass Spectrometry, 2013, 48, 243-249.	0.7	10
137	Trends in analyzing emerging drugs of abuse â€“ from seized samples to body samples. Analytical and Bioanalytical Chemistry, 2014, 406, 6105-6110.	1.9	10
138	Metabolic patterns of JWHâ€210, RCSâ€4, and THC in pig urine elucidated using LCâ€HRâ€MS/MS: Do they reflect patterns in humans?. Drug Testing and Analysis, 2017, 9, 613-625.	1.6	10
139	Liquid Chromatography-High-Resolution Mass Spectrometry-Based In Vitro Toxicometabolomics of the Synthetic Cathinones 4-MPD and 4-MEAP in Pooled Human Liver Microsomes. Metabolites, 2021, 11, 3.	1.3	10
140	Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques?. Biochemical Pharmacology, 2018, 155, 403-418.	2.0	9
141	Evaluation of novel organosilane modifications of paper spray mass spectrometry substrates for analyzing polar compounds. Talanta, 2019, 204, 677-684.	2.9	9
142	Current Situation of the Metabolomics Techniques Used for the Metabolism Studies of New Psychoactive Substances. Therapeutic Drug Monitoring, 2020, 42, 93-97.	1.0	9
143	Can a Recently Developed Pig Model Be Used for In Vivo Metabolism Studies of 7-Azaindole-Derived Synthetic Cannabinoids? A Study Using 5F-MDMB-P7AICA. Journal of Analytical Toxicology, 2021, 45, 593-604.	1.7	9
144	Adherence to Antihypertensive Drugs Assessed by Hyphenated Highâ€Resolution Mass Spectrometry Analysis of Oral Fluids. Journal of the American Heart Association, 2020, 9, e014180.	1.6	9

#	Article	IF	Citations
145	Witnessed drug intake before planned denervationâ€"Always harmless?. International Journal of Cardiology, 2015, 179, 125-126.	0.8	8
146	Analytical characterization of N,Nâ€diallyltryptamine (DALT) and 16 ringâ€substituted derivatives. Drug Testing and Analysis, 2017, 9, 115-126.	1.6	8
147	Microbial biotransformation of five pyrrolidinophenoneâ€type psychoactive substances in wastewater and a wastewater isolated Pseudomonas putida strain. Drug Testing and Analysis, 2017, 9, 1522-1536.	1.6	8
148	Impact of the used solvent on the reconstitution efficiency of evaporated biosamples for untargeted metabolomics studies. Metabolomics, 2020, 16, 34.	1.4	8
149	Toxicokinetic Studies and Analytical Toxicology of the New Synthetic Opioids Cyclopentanoyl-Fentanyl and Tetrahydrofuranoyl-Fentanyl. Journal of Analytical Toxicology, 2020, 44, 449-460.	1.7	8
150	Further development of a liquid chromatographyâ€"highâ€resolution mass spectrometry/mass spectrometryâ€based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or <scp>Ricinus communis</scp> ingestions. Drug Testing and Analysis, 2021, 13, 1603-1613.	1.6	8
151	Studies on the In Vitro and In Vivo Metabolic Fate of the New Psychoactive Substance N-Ethyl-N-Propyltryptamine for Analytical Purposes. Journal of Analytical Toxicology, 2021, 45, 195-202.	1.7	7
152	Comparison of in vitro and in vivo models for the elucidation of metabolic patterns of 7â€azaindoleâ€derived synthetic cannabinoids exemplified using cumylâ€5Fâ€P7AICA. Drug Testing and Analysis, 2021, 13, 74-90.	1.6	7
153	Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis. Molecules, 2021, 26, 1495.	1.7	7
154	Recent trends in drugs of abuse metabolism studies for mass spectrometryâ€"based analytical screening procedures. Analytical and Bioanalytical Chemistry, 2021, 413, 5551-5559.	1.9	7
155	Evaluation and analytical applicability of a novel volumetric absorptive microsampling strategy for adherence monitoring of antihypertensive drugs by means of LC-HRMS/MS. Analytica Chimica Acta, 2021, 1187, 339137.	2.6	7
156	An easy and fast adenosine 5â€²-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5â€²-triphosphatase activity of the human breast cancer resistance protein ABCG2. Journal of Chromatography A, 2017, 1521, 123-130.	1.8	6
157	Transient Receptor Potential Vanilloid 6 (TRPV6) Proteins Control the Extracellular Matrix Structure of the Placental Labyrinth. International Journal of Molecular Sciences, 2020, 21, 9674.	1.8	6
158	Perimortem Distribution of U-47700, Tramadol and Their Main Metabolites in Pigs Following Intravenous Administration. Journal of Analytical Toxicology, 2022, 46, 479-486.	1.7	6
159	In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists QMPSB and QMPCB (SGT-11) Including Isozyme Mapping and Esterase Activity. Metabolites, 2021, 11, 509.	1.3	6
160	Analytical Techniques for the Detection of Novel Psychoactive Substances and Their Metabolites. , 2013, , 131-157.		5
161	Acute combined poisoning with the new designer drug 4-methyl-N-ethyl-cathinone (4-MEC) and gammabutyrolactone (GBL): A case report with different analytical approaches for identification of some metabolites. Toxicologie Analytique Et Clinique, 2014, 26, 119-127.	0.1	5
162	Abuse of nutmeg seeds: Detectable by means of liquid chromatographyâ€mass spectrometry techniques?. Drug Testing and Analysis, 2021, 13, 1440-1444.	1.6	5

#	Article	IF	Citations
163	Drug adherence and psychosocial characteristics of patients presenting with hypertensive urgency at the emergency department. Journal of Hypertension, 2021, 39, 1697-1704.	0.3	5
164	Can the Intake of a Synthetic Tryptamine be Detected Only by Blood Plasma Analysis? A Clinical Toxicology Case Involving 4-HO-MET. Journal of Analytical Toxicology, 2022, 46, 567-572.	1.7	5
165	Induction of Liver Size Reduction in Zebrafish Larvae by the Emerging Synthetic Cannabinoid 4F-MDMB-BINACA and Its Impact on Drug Metabolism. Molecules, 2022, 27, 1290.	1.7	5
166	Photoinduced skin reactions of cardiovascular drugsâ€"a systematic review. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 420-430.	1.4	5
167	Do we need high-resolution MS in forensic and clinical toxicology?. Bioanalysis, 2013, 5, 1161-1163.	0.6	4
168	Cytotoxicity, metabolism, and isozyme mapping of the synthetic cannabinoids JWH-200, A-796260, and 5F-EMB-PINACA studied by means of in vitro systems. Archives of Toxicology, 2021, 95, 3539-3557.	1.9	4
169	Toxicokinetics of U-47700, tramadol, and their main metabolites in pigs following intravenous administration: is a multiple species allometric scaling approach useful for the extrapolation of toxicokinetic parameters to humans?. Archives of Toxicology, 2021, 95, 3681-3693.	1.9	4
170	Overview of Common Designer Drugs. , 2019, , 237-246.		3
171	Altered metabolic pathways elucidated via untargeted in vivo toxicometabolomics in rat urine and plasma samples collected after controlled application of a human equivalent amphetamine dose. Archives of Toxicology, 2021, 95, 3223-3234.	1.9	3
172	Toxic plantsâ€"Detection of colchicine in a fast systematic clinical toxicology screening using liquid chromatographyâ€"mass spectrometry. Drug Testing and Analysis, 2022, 14, 377-381.	1.6	3
173	Forensic and clinical toxicology. Bioanalysis, 2014, 6, 2187-2187.	0.6	2
174	Use of UPLC-HRMS/MS for In Vitro and In Vivo Metabolite Identification of Three Methylphenidate-derived New Psychoactive Substances. Journal of Analytical Toxicology, 2020, 44, 156-162.	1.7	1
175	Reviewing toxicokinetics with a focus on metabolism of new psychoactive substances in the zebrafish (larvae) model. Wiley Interdisciplinary Reviews Forensic Science, 0, , .	1.2	1
176	A simplified strategy to assess the cytotoxicity of new psychoactive substances in HepG2 cells using a high content screening assay â€" Exemplified for nine compounds. Toxicology, 2022, 476, 153258.	2.0	1
177	Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases. Archives of Toxicology, 2022, 96, 2755-2766.	1.9	1
178	Addendum: Hemmer, S., et al. Comparison of Three Untargeted Data Processing Workflows for Evaluating LC-HRMS Metabolomics Data. Metabolites 2020, 10, 378. Metabolites, 2020, 10, 432.	1.3	0
179	Analytical techniques for the detection of novel psychoactive substances and their metabolites. , 2022, , 225-244.		0